Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
about
Targeting the mTOR signaling network for cancer therapyCombining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment.Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further ProposalsPhase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.Signaling mechanisms that suppress the cytostatic actions of rapamycinInvestigating mammalian target of rapamycin inhibitors for their anticancer properties.Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours.Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancerCUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanismsAssembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes.Rapamycin inhibits growth factor-induced cell cycle regulation in pancreatic beta cellsCombination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine.Ginkgo May Sensitize Ovarian Cancer Cells to Cisplatin: Antiproliferative and Apoptosis-Inducing Effects of Ginkgolide B on Ovarian Cancer Cells.Arecoline downregulates levels of p21 and p27 through the reactive oxygen species/mTOR complex 1 pathway and may contribute to oral squamous cell carcinoma.Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during DNA damage-induced apoptosis.mTOR signaling contributes to chondrocyte differentiationRapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin.Knockdown of anion exchanger 2 suppressed the growth of ovarian cancer cells via mTOR/p70S6K1 signaling.p21(WAF1/CIP1) Expression is Differentially Regulated by Metformin and Rapamycin.Areca nut extracts exert different effects in oral cancer cells depending on serum concentration: A clue to the various oral alterations in betel quid chewers.Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage.Cell cycle regulation and anticancer drug discovery.
P2860
Q24658334-8B12D59B-8721-4601-A35C-8522B3197783Q31120012-57DC5254-CB4D-4E0D-A615-241E640429E4Q33760578-7D0CB209-C9B2-4088-BE61-6D563FCB2175Q34130665-0EA1DDC2-EBA8-4654-903E-CA755546539BQ35187701-DCE38E27-025A-4B02-A467-41B315A1C9C6Q36600294-58B30C3A-0FCD-43F0-8940-928753F27708Q36614009-33CA29BB-F7C2-49DC-A707-D5B1ED4318B0Q36715763-7F6367E0-A33C-4B37-BF71-52DE87118009Q36926010-D65DD996-A801-4C69-82D1-EF2F23456AE3Q37154185-19B24D70-6DD7-4737-98DB-56DDDBF1117FQ37172857-1773684B-E245-4A83-9C7B-F836D78A3CA4Q37185312-AACD23AB-A5BB-44C7-B16E-A7A06AE94DFDQ37259485-441EF999-58F1-407C-B500-925E1B11BCEFQ39044822-7209DFD3-F110-4387-ABA3-CAB4DD05D413Q39249148-3A9F6A41-A555-473A-BA1E-D41BBD37156CQ39364337-4C305676-D809-4D49-8FE9-F593257F4328Q39370665-2D562492-404E-46E4-B1A3-4037C7BEA75FQ39887685-A40F6A4D-0A3E-458D-ADC1-2F2A5E9FAA87Q40014562-0D550501-FDBB-44CE-9BBF-22C87D00E270Q40970978-2B0AC167-8F12-4BF0-9945-5BF091109635Q41123353-5873FDD5-E11C-4290-BBF8-98EB07DD1144Q41491502-FE6F2EB9-82E5-4871-BF17-6276D7D7DC75Q41680939-10F169C5-A987-4A94-AF99-A7319CCA7BCEQ45916179-65F39C9C-A9B2-4B98-B54A-6BCBAC84FE34Q49449591-EB735DA1-C3AE-401B-A3E4-853EA5E12108
P2860
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Rapamycin disrupts cyclin/cycl ...... y stabilizing these complexes.
@en
Rapamycin disrupts cyclin/cycl ...... y stabilizing these complexes.
@nl
type
label
Rapamycin disrupts cyclin/cycl ...... y stabilizing these complexes.
@en
Rapamycin disrupts cyclin/cycl ...... y stabilizing these complexes.
@nl
prefLabel
Rapamycin disrupts cyclin/cycl ...... y stabilizing these complexes.
@en
Rapamycin disrupts cyclin/cycl ...... y stabilizing these complexes.
@nl
P2093
P1433
P1476
Rapamycin disrupts cyclin/cycl ...... y stabilizing these complexes.
@en
P2093
Anna Chytil
Bradley Davis
Elizabeth Forrester
Gail Green
Patrick Corsino
Thomas Rowe
P304
P356
10.1158/0008-5472.CAN-05-1672
P407
P577
2006-01-01T00:00:00Z